CN101899010A - 喹唑啉酮衍生物及制备方法和应用 - Google Patents
喹唑啉酮衍生物及制备方法和应用 Download PDFInfo
- Publication number
- CN101899010A CN101899010A CN201010148247XA CN201010148247A CN101899010A CN 101899010 A CN101899010 A CN 101899010A CN 201010148247X A CN201010148247X A CN 201010148247XA CN 201010148247 A CN201010148247 A CN 201010148247A CN 101899010 A CN101899010 A CN 101899010A
- Authority
- CN
- China
- Prior art keywords
- methyl
- derivative
- substituent
- ethyl
- target compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
编号 | 分子式 | 分子量 | H谱 | 元素分析 |
1 | C17H5ClN2O | 298.77 | δ:1.219(t,3H,CH3),2.446(q,2H,CH2CH3),2.488(s,3H,CH3),7.205(dd,J1=2.1Hz,J2=2.1Hz,2H,Ph-2,6),7.533(dd,J1=2.1Hz,J2=2.1Hz,2H,Ph-3,5),7.602-7.651(m,2H,quinazolinon7,8),8.042(s,H,quina-zolinon-5) | C,68.34;H,5.06;Cl,11.87;N,9.38;O,5.36 |
2 | C16H16N4O | 280.32 | δ:1.099(t,3H,C-CH3),2.192(s,3H,CH3),2.271(s,3H,CH3),2.371(q,2H,CH2),6.420(d,J=5.1Hz,1H,pyrimidin-4),7.375(dd,J1=2.1Hz,J2=2.1Hz,1H,quinazolinon-7),7.767(d,J=1.5Hz,1H,quinazoli-non-8),8.052(d,J=5.1Hz,1H,quinazolinon-5),8.384(d,J=8.4Hz,1H,pyrimidin-5) | C,68.55;H,5.75;N,19.99;O,5.71 |
3 | C17H13ClF3N3O | 367.75 | 1H NMR(DMSO,300.13MHz)δ:1.100(t,3H,C-CH3),2.073(s,3H,CH3),2.372(q,2H,CH2),6.772(q,1H,pyrimidin-4),7.185(t,1H,pyrimidin-6),7.379(dd,J1=1.8Hz,J2=1.8Hz,1H,quinazolinon-7),7.767(d,J=1.5Hz,1H,quinazoli-non-8),8.381(d,J=8.7Hz,H,quinazolinon-5) | C,55.52;H,3.56;Cl,9.64;F,15.50;N,11.43;O,4.35 |
4 | C21H21N4O4S | 423.48 | δ:1.096(t,3H,C-CH3),2.277(q,2H,CH2),2.490(s,3H,CH3),6.884(d,J=4.5Hz,1H,isoxazol-4),7.305(d,J=4.5Hz,1H,qu inazolinon-8),7.582-7.686(m,3H,Ph-3,5,quinazolinon-7),7.876(s,1H,quinazoli-non-5),7.947(d,J=8.4Hz,2H,Ph-2,6),12.892(s, | C,59.42;H,4.75;N,13.20;O,15.08;S,7.55 |
H,NH) | ||||
5 | C20H18N4O3S2 | 426.51 | δ:1.498(t,3H,C-CH3),2.284(q,2H,CH2),2.437(s,3H,CH3),5.565(d,J=7.8Hz,1H,2H,thiazol-4,5),6.884(d,J=4.8Hz,1H,quinazol inon-8),7.303(d,J=4.5Hz,1H,quinazolinon-7),7.581-7.659(m,3H,quinazolinon-5,Ph-3,5),7.951(d,J=6.6Hz,2H,Ph-2,6),12.896(s,1H,NH) | C,56.32;H,4.25;N,13.14;O,11.25;S.15.04 |
6 | C22H21N3O4S | 435.50 | δ:1.223(t,3H,CH3),2.316(s,3H,CH3),2.490(s,3H,CH3),2.682(q,2H,CH2),5.575(d,J=5.562Hz,1H,pyri-midin-4),5.983(s,2H,pyrimidin-5,quinazolinon-8),6.537(d,J=8.7Hz,2H,Ph-3,5),6.869(d,J=5.1Hz,1H,quinazolinon-7),7.606(d,J=8.7Hz,2H,Ph-2,6),8.292(d,J=4.8Hz,1H,quinazolinon-5),11.106(s,1H,NH) | C,60.67;H,4.86;N,16.08;O,11.02;S.7.36 |
7 | C21H19N5O3S | 421.47 | δ:1.222(t,3H,C-CH3),2.426(s,3H,CH3),2.668(q,2H,CH2),6.002(s,H,pyrimidin-5),6.534(dd,J1=2.7Hz,J2=2.7Hz,2H,Ph-3,5),7.487(d,J=8.1Hz,1H,quinazolinon-8),7.665(dd,J1=2.1Hz,J2=2.1Hz,2H,Ph-2,6),7.728(d,J=1.5Hz,1H,quina-zolinon-7),8.467(d,J=4.8Hz,2H,pyrimi-din-4,6),11.255(s,1H,NH) | C,59.84;H,4.54;N,16.62;O,11.39;S.7.61 |
8 | C19H21N3O | 307.39 | δ:1.449(t,3H,C-CH3),2.165(s,3H,Ph-2),2.239(s,3H,Ph-5),2.803-2.879(q,2H,CH2-CH3),3.95(s,1H,NH),4.514(s,2H,NCH2),6.424(s,1H,Ph-4),6.515(d,J=7.5Hz,H,Ph-6),6.976(d,J=7.5Hz,1H,Ph-3),7.694(d,J=8.4Hz,1H,quinazolinon H-8),7.807(dd,J1=2.1Hz,J2=2.1Hz,1H, | C,74.24;H,6.89;N,13.67;O.5.20 |
quina-zo linon H-7),8.294(d,J=1.8Hz,1H,quinazolinonH-5),11.794(s,1H,quinazolinonNH). |
9 | C18H19N3O2 | 309.36 | δ:1.213(t,3H,C-CH3),2.584(q,2H,CH2CH3),3.589(s,3H,OCH3),4.352(d,J=6Hz,2H,CH2N),6.066-6.173(m,3H,Ph-2,4,6),6.424(t,1H,NH),6.871-6.938(m,1H,Ph-5H),7.533-7.601(m,1H,quinazolinon H-8),7.728(dd,J1=2.1Hz,J2=2.1Hz,1H,quinazolinon H-7),8.024(d,J=1.5Hz,H,quinazolinonH-5),12.115(s,1H,quinazo linonNH) | C,69.88;H,6.19;N,13.58;O,10.34 |
10 | C23H22N4O | 370.45 | δ:1.218(t,3H,C-CH3),2.493(q,2H,CH2CH3),4.346(d,J=6Hz,2H,CH2N),6.149(t,1H,CH2NH),6.503-6.548(m,2H,Ph-2,6),6.749(d,J=7.8Hz,2H,Ph-3,5),6.839(d,J=8.7Hz,2H,Ph-3`,5`),7.031-7.084(m,3H,Ph-2`,4`,6`),7.496(s,1H,qui-nazolinon H-8),7.554(d,J=8.4Hz,1H,quinazolinonH-5),7.754(dd,J1=2.1Hz,J2=2.1Hz,1H,quinazolinon H-7),8.054(d,J=1.8Hz,1H,Ph-NH-Ph),12.117(s,1H,quinazolinon NH) | C,74.57;H,5.99;N,15.12;O.4.32 |
11 | C16H16N4O | 280.32 | δ:1.211(t,3H,C-CH3),2.605(q,2H,CH2CH3),5.493(s,2H,CH2N),6.864(d,J=7.2Hz,2H,pyridin2,6),7.627(d,J=8.4Hz,1H,quinazolinon H-8),7.783(dd,J1=2.1Hz,J2=2.1Hz,1H,quinazolinon H-7),8.06(d,J=1.8Hz,1H,quinazolinon H-5),8.224(s,1H,NHCH2),8.341(d,J=7.2Hz,2H,pyri-din3,5),12.277(s,1H,quinazolinon NH) | :C,68.55;H,5.75;N,19.99;O,5.71 |
12 | C20H19N5O3S2 | 441.53 | δ:1.207(t,3H,C-CH3),2.603(q,2H,CH2CH3),5.197(s,2H,CH2NH),5.842(s,2H,NH), | C,54.41;H,4.34;N,15.86; |
5.842(s,2H,NHCH2,NHSO2),6.465(dd,J1=1.8Hz,J2=1.8,2H,Ph-2,6),6.861(d,J=4.8Hz,1H,thiazole-3),7.354(d,J=2.7Hz,2H,Ph-3,5),7.535(d,J=4.8Hz,1H,thiazole-4),7.573(d,J=2.1Hz,1H,quinazoli-nonH-8),7.601(d,J=2.1Hz,1H,quinazolinon H-5),7.984(d,J=1.8Hz,1H,quinazolin-on H-7),12.219(s,1H,quinazolinon NH). | O,10.87;S,14.52 |
13 | C21H20N6O3S | 434.49 | δ:1.220(t,3H,C-CH3),2.583(q,2H,CH2CH3),5.414(s,2H,CH2NH),6.104(s,2H,NH,NH),6.526(d,J=8.7Hz,Ph-2,6),6.938(d,J=5.1Hz,1H,yrimidin-4),7.495(d,J=8.4Hz,1H,yrimidin-3),7.617(d,J=8.7Hz,1H,yrimidin-5),7.723(d,J=2.1Hz,2H,Ph-3,5),7.751(dd,J1=2.1Hz,J2=2.1Hz,1H,quinazolinon H-7),8.06(d,J=1.8Hz,1H,quinazolinon H-8),8.359(d,J=5.1Hz,1H,quinazol inon H-5),12.147(s,1H,quinazolinon NH). | C,57.79;H,4.62;N,19.25;O,11.00;S.7.35 |
14 | C21H21N5O4S | 439.49 | δ:1.214(t,3H,C-CH3),2.295(s,3H,isoxazole-CH3),2.487(q,2H,CH2CH3),4.939(s,2H,CH2NH),6.258(s,2H,NHCH2,NHSO2),6.438(d,J=0.90Hz,1H,isoxazole-5H),6.583(d,J=2.1Hz,2H,Ph-2,6),7.473(d,J=8.7Hz,2H,Ph-3,5),7.553(d,J=8.4Hz,1H,quinazolinon H-8),7.710(dd,J1=2.1Hz,J2=2.1Hz,1H,quinazol inon H-7),8.024(d,J=1.8Hz,1H,quinazolinon H-5),12.178(s,1H,quinazolinon NH) | C,57.39;H,4.82;N,15.94;O,14.56;S,7.30 |
15 | C23H24N6O3S | 464.54 | δ:1.244(t,3H,C-CH3),2.328(t,6H,pyrimidine-3,5CH3),3.727(q,2H,CH2CH3),5.572(s,2H,CH2NH),6.569(d,J=8.7Hz,2H,NH,NH),6.594(d,J=2.4 | C,59.47;H,5.21;N,18.09;O,10.33;S,6.90 |
Hz,2H,Ph-2,6),6.644(d,J=8.7Hz,1H,pyrimidine-4),7.911(d,J=2.4Hz,1H,quinazolinonH-8),7.936(d,J=0.90Hz,1H,quinazo-linon H-5),8.412(d,J=1.5Hz,1H,quinazolinon H-7),12.185(s,1H,quinazolinon NH). | ||||
16 | C19H29N3O | 315.45 | δ:0.887(t,3H,octan-CH3),1.292-1.215(m,14H,octan-3-7CH2),1.405(t,3H,quinazolinon-CH3),2.665(t,3H,octan-2CH2),2.806(q,2H,quinazo-linon-CH2CH3),3.221(d,J=6.6Hz,1H,NH),3.946(s,2H,CH2NH),7.664(d,J=8.1Hz,1H,quinazolinon H-8),7.763(d,J=1.8Hz,1H,quina-zolinonH-5),8.206(d,J=1.8Hz,1H,quinazolinon H-7),12.167(s,1H,qui-nazolinon NH). | C,72.34;H,9.27;N,13.32;O.5.07 |
17 | C17H19N3O | 281.35 | δ:1.1743(t,3H,C-CH3),2.497(s,2H,pyridine-6),2.611(q,2H,CH2CH3),3.029-3.118(m,3H,pyridine-3),5.910(s,2H,CH2),7.65(d,J=8.4Hz,1H,pyridine-2),7.923(dd,J1=2.1Hz,J2=2.1Hz,1H,pyridine-4),8.059-8.105(m,1H,pyridine-5),8.277(d,J=2.1Hz,1H,quinazo-linon-8),8.469(d,J=7.8Hz,1H,quinazolinon-5),9.094(d,J=6Hz,1H,quinazolinon-7),12.317(s,1H,quinazolinon NH). | C,72.57;H,6.81;N,14.94;O.5.69 |
18 | C14H14N4O | 254.29 | δ:1.213(t,3H,C-CH3),2.493(q,2H,CH2CH3),5.319(s,2H,CH2NH),6.918(s,1H,imidazole-4H),7.221(s,1H,imidazo-le-5H),7.577(d,J=8.4Hz,1H,quinazolinon H-8),7.653(dd,J1=2.1Hz,J2=2.1Hz,1H,quina-zolinon H-7),7.895(d,J=1.5Hz,1H,quinazolinon H-5),7.939(s,1H,imi-dazole-2H), | C,66.13;H,5.55;N,22.03;O,6.29 |
12.196(s,1H,quinazo-linon NH) | ||||
19 | C16H21N3O | 271.36 | δ:1.242(t,3H,C-CH3),1.317-1.517(m,6H,piperidine-3,4,5),2.368-2.507(m,4H,piperidine-2,4),2.617(q,2H,CH2CH3),3.618(d,J=3.9Hz,2H,CH2),7.508(s,1H,quinazolinon-8),7.579(s,1H,qui-nazolinon-5),8.001(s,1H,quinazolinon-7),12.150(s,1H,quinazolinon NH) | C,70.82;H,7.80;N,15.49;O.5.90 |
20 | C18N16F3N3O | 347.33 | δ:1.220(t,3H,C-CH3),2.602(q,2H,CH2CH3),4.453(d,J=3.6Hz,2H,CH2NH),6.795-6.908(m,4H,NH,3-trifluo-romethyl-phenylamino-2,4,6),7.243(t,1H,Ph-5),7.748(d,J=1.2Hz,1H,quinazolinon-8),7.765(d,J=1.2Hz,1H,quinazolinon-7),8.056(s,1H,quinazolinon-5),12.134(s,H,quina-zolinon NH) | C,62.24;H,4.64;F,16.41;N,12.10;O.4.61 |
21 | C19H21N3O2 | 323.29 | δ:1.223(t,6H,CH3,),2.601(q,2H,CH2CH3),3.841(q,2H,CH2O),4.325(d,J=5.5Hz,2H,CH2NH),5.977(s,1H,NH),6.493(d,J=4.5Hz,2H,Ph-2,6),6.569(d,J=4Hz,2H,Ph-3,5),7.55(d,J=8Hz,1H,quinazolinon-8),7.743(s,J=8Hz,1H,quinazoli-non-7),8.542(s,1H,quinazolinon-5),12.104(s,1H,quinazolinon NH) | C,70.57;H,6.55;N,12.99;O.9.89 |
22 | C15H15N3O4 | 301.30 | δ:1.235(t,3H,C-CH3),2.609-2.733(m,6H,CH2,pyrrolidine-2,5-dione-3,4),5.126(s,2H,CH2O),7.609(d,J=8.5Hz,1H,quinazolinon-8),7.875(dd,J1=2.0Hz,J2=2.0Hz,1H,qui-nazolinon-7),8.168(s,1H,quina-zolinon-5),12.239(s,1H,quinazolinon NH) | C,59.79;H,5.02;N,13.95;O.21.24 |
23 | C16H13Cl2N7O | 390.23 | δ:1.258(t,3H,C-CH3),2.650(q,2H,CH2),3.204(q,1H,NH),6.763(s,2H,CH2),7.712(d,J= | C,49.25;H,3.36;Cl,18.17; |
8.5Hz,1H,quinazo-linon-8),7.861(dd,J1=2.0Hz,J2=2.0Hz,1H,quinazolinon-7),7.960(s,1H,quinazolinon-5),8.093(s,1H,purin-7),12.852(s,1H,quinazolinon NH). | N,25.13;O,4.10 |
24 | C17H23N3O | 285.38 | δ:0.878(t,3H,C-CHH3),1.089-1.525(m,6H,CH3,piperidin-3,4),1.563(d,J=1.2Hz,H,piperidin-5),1.934(t,2H,piperidin-2),2.584(q,2H,CH2),2.743(d,2H,piperidin-6),3.525(s,2H,CH2),7.532(d,J=8.4Hz,1H,quinazoli-non-8),7.665(dd,J1=2.1Hz,J2=2.1Hz,1H,quinazolinon-7),7.943(d,J=1.5Hz,H,quinazolinon-5),12.165(s,1H,quinazolinon NH). | C,71.55;H,8.12;N,14.72;O.5.61 |
25 | C17H25N3O | 287.4 | δ:0.874(t,3H,C-CH3),1.253-1.443(m,11H,CH3CH2CH2CH2CH2),1.564(t,1H,NH),2.701(t,2H,CH2),2.791(q,2H,CH2CH3),3.977(s,2H,CH2),7.659(d,J=8.4Hz,1H,quinazoli-non-8),7.789(dd,J1=1.8Hz,J2=1.8Hz,1H,quinazolinon-7),8.233(s,1H,quinazolinon-5),12.145(s,1H,quinazo linon NH) | C,71.04;H,8.77;N,14.62;O,5.57 |
26 | C16H25N4O | 286.37 | δ:1.437(t,3H,C-CH3),2.382(s,4H,piperazin-3,5),2.595(s,3H,CH3),2.816(q,2H,CH2),2.892(d,J=0.6Hz,2H,piperazin-2),2.966(d,J=0.3Hz,2H,piperazin-6),3.653(s,2H,CH2),7.666(d,J=8.1Hz,1H,quina-zolinon-8),7.768(dd,J1=2.1Hz,J2=2.1Hz,1H,quinazolinon-7),8.170(s,1H,quinazolinon-5),12.210(s,1H,quinazolinon NH) | C,67.11;H,7.74;N,19.56;O,5.59 |
27 | C17H23N3O | 285.38 | δ:1.219-1.603(m,12H,CH3,CH3,6H,piperidine-3,4,5,2.068(s,1H,piperi-dine-2),2.484-2.627(m,4H,CH2,2H, | C,71.55;H,8.12;N,14.72;O.5.61 |
piperi-dine-6),4.014(s,2H,CH2),7.532(d,1H,quinazolinon-8),7.674(dd,J1=1.5Hz,J2=1.5Hz,1H,quina-zolinon-7),7.957(s,1H,quinazolinon-5),12.130(s,1H,NH) |
化合物编号 | 化合物熔点(℃) | 化合物编号 | 化合物熔点(℃) |
1 | 185-186 | 15 | 139-140 |
2 | 212-214 | 16 | 158-159 |
3 | 187-188 | 17 | 217-218 |
4 | 260-261 | 18 | 197-198 |
5 | 214-216 | 19 | 219-220 |
6 | 216-217 | 20 | 200-202 |
7 | 218-220 | 21 | 199-200 |
8 | 218-220 | 22 | 277-278 |
9 | 206-207 | 23 | 209-210 |
10 | 220-222 | 24 | 209-211 |
11 | 308-309 | 25 | 157-158 |
12 | 300-301 | 26 | 222-223 |
13 | 229-230 | 27 | 186-188 |
14 | 211-212 |
Claims (27)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010148247 CN101899010B (zh) | 2010-04-15 | 2010-04-15 | 喹唑啉酮衍生物及制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010148247 CN101899010B (zh) | 2010-04-15 | 2010-04-15 | 喹唑啉酮衍生物及制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101899010A true CN101899010A (zh) | 2010-12-01 |
CN101899010B CN101899010B (zh) | 2013-08-21 |
Family
ID=43224973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010148247 Expired - Fee Related CN101899010B (zh) | 2010-04-15 | 2010-04-15 | 喹唑啉酮衍生物及制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101899010B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102382054A (zh) * | 2011-09-07 | 2012-03-21 | 中国人民解放军第二军医大学 | 吡唑、异噁唑衍生物及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657893A (en) * | 1984-05-09 | 1987-04-14 | Syntex (U.S.A.) Inc. | 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors |
WO2008140750A1 (en) * | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
-
2010
- 2010-04-15 CN CN 201010148247 patent/CN101899010B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657893A (en) * | 1984-05-09 | 1987-04-14 | Syntex (U.S.A.) Inc. | 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors |
WO2008140750A1 (en) * | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
Non-Patent Citations (4)
Title |
---|
《Current Science》 19570331 H.L.Bami et al Potentiality of quinazolone derivatives as antimalarials 第85-86页 1、23 第26卷, 第3期 2 * |
《药学实践杂志》 20100725 宁微微等 新型喹唑啉酮类先导物的设计、合成及抑制人顶体酶活性研究 第296-298、312页 1-27 第28卷, 第4期 2 * |
H.L.BAMI ET AL: "4(3)-quinazolone derivatives as potential antimalarials: part I - some 2-alkyl-3-substituted-phenyl-6-alkyl-(or halo)-4(3)-quinazolones", 《JOURNAL OF SCIENTIFIC & INDUSTRIAL RESEARCH B》 * |
H.L.BAMI ET AL: "4(3)-quinazolone derivatives as potential antimalarials: part I - some 2-alkyl-3-substituted-phenyl-6-alkyl-(or halo)-4(3)-quinazolones", 《JOURNAL OF SCIENTIFIC & INDUSTRIAL RESEARCH B》, vol. 16, 31 December 1957 (1957-12-31), pages 558 - 562 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102382054A (zh) * | 2011-09-07 | 2012-03-21 | 中国人民解放军第二军医大学 | 吡唑、异噁唑衍生物及其制备方法和应用 |
CN102382054B (zh) * | 2011-09-07 | 2014-12-24 | 中国人民解放军第二军医大学 | 异噁唑衍生物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101899010B (zh) | 2013-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105837575B (zh) | 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途 | |
CN101511798A (zh) | 作为蛋白激酶抑制剂的[4,5′]联嘧啶-6,4′-二胺衍生物 | |
CN102898386B (zh) | 喹唑啉衍生物、其制备方法、中间体、组合物及其应用 | |
CN101687821A (zh) | 蛋白激酶抑制剂及其使用方法 | |
CN104803925B (zh) | 一类以fgfr为靶点的2,4,5‑三取代嘧啶类化合物及其制备方法和用途 | |
CN104902959A (zh) | Irak抑制剂和其用途 | |
MX2008014618A (es) | Composiciones y metodos para inhibidores de cinasas del receptor fgf. | |
CN109134448A (zh) | 杂环化合物及其盐、制备方法、用途和药物 | |
CN111377907B (zh) | 一种多取代苯氨基嘧啶衍生物及其制备方法和用途 | |
CN108658990B (zh) | 一类新型咪唑并[1,5-a]吡嗪类布鲁顿激酶抑制剂 | |
CN101899010B (zh) | 喹唑啉酮衍生物及制备方法和应用 | |
Modica et al. | High affinity and selectivity of [[(arylpiperazinyl) alkyl] thio] thieno [2, 3-d] pyrimidinone derivatives for the 5-HT1A receptor. Synthesis and structure–affinity relationships | |
CN108329274A (zh) | 布鲁顿酪氨酸激酶抑制剂 | |
JP7266901B2 (ja) | 複素環式化合物、調製方法及びその医薬的な応用 | |
CN112778282A (zh) | 一种嘧啶类小分子化合物及其应用 | |
CN104876860B (zh) | 一种二芳基吡啶衍生物及其制备方法与应用 | |
CN104262263B (zh) | 一种N,6二苯基嘧啶-4-胺类Bcr-Abl抑制剂及其制备方法和应用 | |
CN115785080A (zh) | 一种尿嘧啶母核类化合物及其制备方法和应用 | |
CN110305125A (zh) | 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用 | |
CN104817535A (zh) | 一种喹啉酮衍生物及其合成方法及应用 | |
CN112047932B (zh) | 吡唑类脾酪氨酸激酶抑制剂及其制备方法与用途 | |
CN111961035B (zh) | 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用 | |
CN106674200B (zh) | 一种含有l-脯氨酰胺片段的化合物及其制备方法和应用 | |
CN108164548A (zh) | 嘧啶并吗啉衍生物及其制备方法和用途 | |
CN101955465A (zh) | 一种5-氟嘧啶-4(3h)-酮类化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Lv Jiaguo Inventor after: Zhang Ling Inventor after: Liu Xuefei Inventor after: Qi Jingjing Inventor after: Ning Weiwei Inventor after: Zhu Ju Inventor after: Zhou Youjun Inventor after: Song Yunlong Inventor after: Xue Boliang Inventor after: Sheng Chunquan Inventor after: Wu Yunqi Inventor after: Zheng Canhui Inventor before: Lv Jiaguo Inventor before: Zhang Ling Inventor before: Liu Xuefei Inventor before: Qi Jingjing Inventor before: Ning Weiwei Inventor before: Zhu Ju Inventor before: Zhou Youjun Inventor before: Song Yunlong Inventor before: Xue Boliang Inventor before: Sheng Chunquan Inventor before: Wu Yunqi Inventor before: Zheng Canhui |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130821 Termination date: 20150415 |
|
EXPY | Termination of patent right or utility model |